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Abstract
Background: The mechanism of in-stent restenosis (ISR) is multifactorial, which includes biological, 
mechanical and technical factors. This study hypothesized that increased inflammatory reaction, which 
is known to be an important atherosclerotic process, at a culprit lesion may lead to higher restenosis 
rates.
Methods: The study population consisted of 241 patients who had undergone percutaneous coronary 
intervention with virtual histology-intravascular ultrasound (VH-IVUS) and a 9-month follow-up 
coronary angiography. Compared herein is the coronary plaque composition between patients with ISR 
and those without ISR. 
Results: Patients with ISR (n = 27) were likely to be older (66.2 ± 9.5 years vs. 58.7 ± 11.7 years,  
p = 0.002) and have higher levels of high-sensitivity C-reactive protein (hs-CRP, 1.60 ± 3.59 mg/dL vs. 
0.31 ± 0.76 mg/dL, p < 0.001) than those without ISR (n = 214). VH-IVUS examination showed that 
percent necrotic core volume (14.3 ± 8.7% vs. 19.5 ± 9.1%, p = 0.005) was higher in those without 
ISR than those with ISR. Multivariate analysis revealed that hs-CRP (odds ratio [OR] 3.334, 95% con-
fidence interval [CI] 1.158–9.596, p = 0.026) and age (OR 3.557, 95% CI 1.242–10.192, p = 0.018) 
were associated with ISR.
Conclusions: This study suggests that ISR is not associated with baseline coronary plaque composition 
but is associated with old age and increased expression of the inflammatory marker of hs-CRP. 
(Cardiol J 2018; 25, 1: 7–13)
Key words: intravascular ultrasonography, coronary artery disease, myocardial  
ischemia, inflammation, coronary stenosis
Introduction
Over recent decades, percutaneous coronary 
intervention (PCI) techniques have improved ex-
traordinarily. In particular, the introduction of the 
drug-eluting stent (DES) reduced the prevalence 
of in-stent restenosis (ISR) and the re-intervention 
rate compared to the bare-metal stent. Rates of 
target lesion revascularization were as high as 
20% with the bare metal stent compared to the 
single-digit rates with DES [1, 2]. However, despite 
the extensive introduction of DESs, ISR did not 
disappear and is still causing problems in high-risk 
patients and complex lesions [3–5].
The mechanisms involved in ISR include bio-
logical, mechanical, and technical factors. The me-
chanical and technical factors related to ISR can be 
overcome by using new-generation polymer-free 
DESs, intracoronary imaging and/or high-pressure 
ballooning, which eliminate stent malapposition, 
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total lesion coverage, and stent edge dissection. 
Inflammation, which is an important mechanism 
of atherosclerosis, is also known as an important 
factor in the restenosis process. The inflammatory 
process includes platelet deposition, leukocyte 
recruitment, and smooth muscle cell migration and 
proliferation [6, 7]. These inflammatory processes 
were seen in human and rabbit models after stent-
ing. Inflammation after stenting in human was more 
profound in damaged media in contact with the 
stent. In addition, the inflammatory cytokine CD 11b 
was increased in patients with restenosis [8].
Therefore, we hypothesized that a greater 
inflammatory reaction at the culprit lesion may lead 
to higher restenosis rates. The objective of this 
study was to compare plaque composition, which 
represents plaque inflammatory status, in patients 
with ISR and those without ISR.
Methods
Study population
The study population consisted of 331 con-
secutive patients of PCI and virtual histology-in-
travascular ultrasound (VH-IVUS) at the Konyang 
University Hospital. Ninety patients were excluded 
because they did not undergo the 9-month follow-
up coronary angiography (CAG) mainly due to no 
subjective symptoms and inconvenience. A total of 
241 patients who underwent PCI with stenting and 
VH-IVUS as well as the 9-month follow-up CAG 
were enrolled in this study. An ISR was defined 
as the presence of over 50% diameter stenosis 
by visual assessment in the stented lesion [9]. 
Twenty-seven (11.2%) patients had ISR, whereas 
214 (88.8%) patients showed no ISR. The an-
giographic findings were reviewed by two blinded 
cardiologists. Another cardiologist gave an opinion 
if the 2 cardiologists disagreed about the ISR.
Demographic data of the study population 
were confirmed by chart review. Coronary risk 
factors included hypertension (blood pressure 
≥ 140/90 mm Hg based on the average of repeated 
readings or the presence of antihypertensive drug 
therapy), dyslipidemia (total cholesterol > 200 mg/dL 
and/or triglyceride > 150 mg/dL and/or low-density 
lipoprotein cholesterol > 130 mg/dL or patients 
on lipid-lowering therapy), diabetes mellitus (con-
trolled with diet, oral hypoglycemic agents, or 
insulin, fasting glucose levels ≥ 126 mg/dL, or 2 h 
oral glucose tolerance test ≥ 200 mg/dL), and cur-
rent cigarette smoking. This study was approved 
by the ethics committee of the Konyang University 
Hospital and was in accordance with the Declara-
tion of Helsinki.
PCI
All patients received 300 mg aspirin, 300–600 
mg clopidogrel, and 120 IU/kg of unfractionated 
heparin intravenously before PCI. PCI was per-
formed via the radial or femoral approach using 5, 
6 or 7 Fr guiding catheter and 0.014-inch standard 
or extra-support coronary guidewires. The culprit 
lesion was identified by ventricular wall motion ab-
normalities and the appearance of the angiographic 
lesion. All study subjects underwent successful 
PCI at the culprit lesion and VH-IVUS examination.
IVUS examination and analysis
VH-IVUS examination was performed on 
the culprit lesion with a dedicated 20-MHz, 2.9 F 
monorail, electronic Eagle Eye Gold IVUS catheter 
(Volcano Therapeutics, Rancho Cordova, Califor-
nia) and VH-IVUS console (Volcano Therapeutics, 
Rancho Cordova, California) during the CAG after 
intracoronary administration of 100–200 µg nitro-
glycerin. The IVUS catheter was advanced into 
the target lesion after wiring or ballooning and 
an automatic pullback at 0.5 mm/s was done. The 
VH-IVUS image was recorded on a DVD-ROM for 
offline analysis.
Both qualitative and quantitative analyses of 
grayscale IVUS images were performed according 
to the criteria of the American College of Cardiol-
ogy’s Clinical Expert Consensus Document on 
IVUS [10–12]. The proximal and distal references 
were defined as the sites with the largest lumen 
that were proximal and distal to the stenosis but 
within the same segment (usually within 10 mm of 
the stenosis with no major intervening branches), 
respectively.
The cross-sectional area (CSA) of the ex-
ternal elastic membrane (EEM) was measured 
with customized software (IVUS lab., Volcano 
Therapeutics, Rancho Cordova, CA, USA). The 
remodeling index was calculated as the lesion EEM 
CSA divided by the average reference EEM CSA.
Spectral analysis of the IVUS  
radiofrequency data
The following analyses were conducted on the 
target lesion with customized software (IVUS Lab.; 
Volcano Therapeutics, Rancho Cordova, California) 
by an examiner who was unaware of the grayscale 
IVUS results. For both the lumen and the media-
adventitia interface, automatic border detection 
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was done at the predefined lesion segment. The 
border detection was manually corrected in the 
lesion after automatic border detection. Border 
detection required the agreement of two independ-
ent experienced cardiologists (KTG and PHW). 
Disagreements were reviewed by a third cardiolo-
gist (BJH). After confirming the border detection, 
the software automatically calculated and showed 
the results. For each frame, the histologic find-
ings were expressed in colors (green for fibrous, 
green-yellow for fibro-fatty, white for dense calci-
fied, and red for necrotic core area). The predictive 
accuracy of this method with tissue mapping has 
been validated [13]. The area (mm2) and percent 
area of each tissue component of the plaque were 
analyzed at the minimal luminal area site, and the 
volume (mm3) and the percent volume of each 
tissue component of the plaque were evaluated at 
a full segment of the culprit lesion. Volume was 
divided by lesion length to adjust for the different 
lesion lengths of each patient, and this was reported 
as the corrected volume (mm3/mm). 
Statistical analysis
All analyses were performed with SPSS (ver-
sion 18.0; SPSS Inc., Chicago, Illinois). All data 
were expressed as the mean ± standard deviation 
for continuous variables and as percentage ratios 
for categorical variables. Categorical variables were 
compared by the c2 test. Continuous variables were 
compared by independent t-tests. Binary logistic 
regression analyses were performed to determine 
the independent factors for ISR. A p value < 0.05 
was considered statistically significant.
Results
Demographics
The patients with ISR (n = 27, 11.2%) were 
likely to be older (66.2 ± 9.5 years old vs. 58.7 ± 
± 11.7 years old, p = 0.002) and have higher high-
sensitivity C-reactive protein (hs-CRP) expres-
sion (1.60 ± 3.59 mg/dL vs. 0.31 ± 0.76 mg/dL, 
p < 0.001) than those without ISR (n = 214, 88.8%). 
In addition, patients with ISR were more likely to 
take beta-blockers (88.9% vs. 70.0%, p = 0.046) 
than those without ISR. Other demographic find-
ings, such as risk factors, medication and other 
blood chemistry, showed no significant differences 
between the two groups (Table 1).
Angiographic findings also showed no signifi-
cant differences between the two groups in terms 
of treated vessel, inserted stent type, length and 
diameter (Table 2).
IVUS findings
Grayscale IVUS findings also showed no signif-
icant differences between the two groups (Table 3). 
Baseline volumetric VH-IVUS findings over the 
lesion length showed smaller necrotic core volume 
(14.2 ± 12.7 mm3 vs. 22.1 ± 19.9 mm3, p = 0.045) 
and percent necrotic core volume (14.3 ± 8.7% 
vs. 19.5 ± 9.1%, p = 0.005) in patients with ISR 
compared to those without ISR by univariate 
analysis. However, percent fibrofatty volume was 
larger (16.6 ± 9.7% vs. 12.4 ± 8.4%, p = 0.018) 
by univariate analysis in patients with ISR than in 
those without ISR. Baseline lesion analysis at the 
minimal luminal area showed no significant differ-
ences between the two groups (Table 4). Fibro-
calcific atheroma was the most frequent lesion type 
(n = 10, 37.0%) in patients with ISR, whereas thin 
cap fibroatheroma (n = 103, 48.1%) was the most 
common type in those without ISR.
Independent factors for ISR
Binary logistic regression analyses showed 
that the VH-IVUS findings did not have any signifi-
cant impact on ISR rates in this study population. 
When we performed the analysis in those with 
acute coronary syndrome and those with stable 
angina, there were no significant factors for ISR. 
Old age and higher hs-CRP were the significant 
independent factors for ISR in this study (Table 5).
Discussion
The main findings of this study are as follows: 
first, old age and high inflammatory status, which 
was reflected by a high serum hs-CRP level, were 
associated with ISR in patients with DES implanta-
tion; second, baseline plaque composition did not 
have an impact on ISR in patients in the present 
study.
Introduction of the DES significantly reduced 
ISR due to the anti-inflammatory, immunomodu-
latory, and/or antiproliferative actions of coated 
drugs. However, ISR is still a major limitation of 
DESs, which is caused by biological (drug resist-
ance and hypersensitivity), mechanical (stent 
underexpansion, nonuniform drug distribution, and 
stent fracture), and technical factors (barotraumas 
outside stented segment, stent gap, and residual 
uncovered atherosclerotic plaques) [6]. A study 
showed that inflammatory cytokine-associated ne-
ointimal hyperplasia resulted in granuloma forma-
tion and reactive inflammatory infiltration, which 
is a main etiology of ISR in stented vessels in the 
pig coronary restenosis model [14]. Inflammatory 
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reaction is also important in ISR in humans. Inflam-
matory reaction after coronary stenting leads to 
vascular injury, and secondary inflammation acti-
vates smooth muscle cells to transform, migrate, 
and proliferate, ultimately inducing neointima 
formation, which contributes to coronary ISR [15].
A recent study has also shown the association 
of higher and more-prolonged CRP plasma levels 
and ISR [16]. Moreover, the degree of initial coro-
nary plaque inflammation, which was reflected by 
hs-CRP level, associated with coronary in-stent 
restenosis after PCI in recurrent unstable angina. 
Table 1. Baseline patient demographics.
ISR (+); n = 27 (11.2%) ISR (–); n = 214 (88.8%) P
Characteristics:
Age [years] 66.2 ± 9.5 58.7 ± 11.7 0.002
Male 16 (59.3%) 156 (72.9%) 0.140
Ejection fraction [%] 66.2 ± 9.7 62.8 ± 10.3 0.113
Old MI 3 (11.1%) 8 (3.7%) 0.084
Stable angina 19 (70.4%) 114 (53.3%) 0.092
ACS 8 (29.6%) 100 (46.7%) 0.092
Unstable angina 3 (11.1%) 21 (9.8%%)
NSTEMI 2 (7.4%) 15 (7.0%)
STEMI 3 (11.1%) 64 (29.9%)
Risk factors:
Current smoking 7 (25.9%) 87 (40.7%) 0.130
Diabetes 11 (40.7%) 55 (25.7%) 0.105
Hypertension 18 (66.7%) 111 (51.9%) 0.160
Dyslipidemia 6 (22.2%) 81 (37.9%) 0.126
Medications:
Aspirin 27 (100%) 211 (98.6%) 0.721
Statins 22 (81.5%) 192 (89.7%) 0.146
ACEI 16 (59.3%) 134 (62.6%) 0.689
ARB 1 (3.7%) 22 (10.3%) 0.268
BB 24 (88.9%) 150 (70.0%) 0.046
CCB 2 (7.4%) 24 (11.2%) 0.539
OHA 9 (33.3%) 41 (19.1%) 0.092
Insulin 0 (0%) 7 (3.3%) 0.338
Laboratory:
Total cholesterol [mg/dL] 183 ± 42 194 ± 56 0.324
Triglyceride [mg/dL] 174 ± 105 174 ± 145 0.988
HDL cholesterol [mg/dL] 41.5 ± 9.8 44.3 ± 10.7 0.207
LDL cholesterol [mg/dL] 121 ± 30 125 ± 33 0.515
Creatinine [mg/dL] 1.06 ± 0.24 1.00 ± 0.21 0.162
hs-CRP [mg/dL] 1.60 ± 3.59 0.31 ± 0.76 < 0.000
At the time of FU CAG:
Death 0 (0%) 0 (0%)
Ischemic driven 11 (40.7%) 27 (12.6%) < 0.000
Acute MI 4 (14.8%) 0 (0%) < 0.000
Repeat PCI 13 (48.1%) 0 (0%) < 0.000
ISR — in-stent restenosis; MI — myocardial infarction; ACS — acute coronary syndrome; NSTEMI — non-ST-elevation myocardial infarction; 
STEMI — ST-elevation myocardial infarction; ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin receptor blockers; BB — 
beta-blockers; CCB — calcium channel blockers; OHA — oral hypoglycemic agents; HDL — high-density lipoprotein; LDL — low-density lipo-
protein; hs-CRP — high-sensitivity C-reactive protein; FU CAG — follow-up coronary angiography; PCI — percutaneous coronary intervention
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Pathogenesis of atherosclerosis includes foam cell 
accumulation in the smooth muscle and endothelial 
cell layers after oxidation of low-density lipoprotein 
cholesterol by macrophages. This pathogenesis is 
associated with inflammatory reactions, and the 
death of these foam cells ultimately causes necrotic 
core formation [17].
Therefore, it was hypothesized that the in-
flammatory coronary plaque composition, such as 
necrotic core and lipid component in this study, may 
be associated with ISR development. However, this 
study did not reveal any significant associations 
between coronary plaque composition and ISR 
development. The inflammatory atherosclerotic 
process can occur naturally after coronary stent-
ing due to increased mechanical and biological 
stress-induced smooth muscle cell proliferation 
and neointimal hyperplasia. Thus, inflammation 
after coronary stenting could be more important 
than prior plaque composition in terms of ISR. For 
this reason, the baseline necrotic core volume and/ 
/or fibrofatty component were not correlated with 
ISR in the multivariate analysis of this study.
A previous study revealed that old age is an eti-
ology of ISR [18]. In this study, ISR occurred in al-
most twice as many patients who were over 75 years 
old than in patients under 75 years old (p < 0.001) 
and this result was explained by lower ejection frac-
Table 2. Baseline angiographic and procedural findings.
ISR (+); n = 27 (11.2%) ISR (–); n = 214 (88.8%) P
Multivessel disease 9 (33.3%) 49 (22.9%) 0.104
Treated vessel: 0.783
LAD 13 (48.1%) 124 (57.9%)
LCX 7 (26.0%) 32 (15.0%)
RCA 6 (22.2%) 47 (22.0%)
LMT 1 (3.7%) 9 (4.2%)
Stents type: 0.111
Cypher 4 (14.8%) 103 (48.1%)
Taxus 5 (18.5%) 37 (17.3%)
Endeavor Resolute 5 (18.5%) 32 (15.0%)
Pico Elite 5 (18.5%) 33 (15.4%)
Stent length [mm] 23 ± 6 23 ± 5 0.449
Stent diameter [mm] 3.1 ± 0.5 3.3 ± 1.7 0.498
ISR — in-stent restenosis; LAD — left anterior descending coronary artery; LCX — left circumflex coronary artery; RCA — right coronary  
artery; LMT — left main trunk
Table 3. Baseline grayscale intravascular ultrasound findings.
ISR (+); n = 27 (11.2%) ISR (–); n = 214 (88.8%) P
Lesion length [mm] 16.4 ± 7.1 19.1 ± 7.9 0.096
Remodeling index 0.97 ± 0.18 0.98 ± 0.19 0.692
Volumetric analysis [mm3]:
Lumen volume 100.0 ± 49.9 116.0 ± 64.3 0.213
Vessel volume 250 ± 136 294 ± 170 0.205
Plaque volume 150 ± 93 178 ± 112 0.219
Lesion analysis at MLA [mm2]:
Lumen area 4.16 ± 1.38 3.86 ± 1.18 0.224
Vessel area [mm2] 14.7 ± 4.6 15.2 ± 5.7 0.640
Plaque area [mm2] 10.5 ± 4.0 11.4 ± 5.2 0.396
ISR — in-stent restenosis; MLA — minimal luminal area
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Table 4. Baseline virtual histology-intravascular ultrasound findings.
ISR (+); n = 27 (11.2%) ISR (–); n = 214 (88.8%) P
Volumetric analysis:
Fibrous [mm3] 58.4 ± 44.3 67.1 ± 52.2 0.406
Fibrofatty [mm3] 16.0 ± 18.2 15.6 ± 18.0 0.897
Dense calcium [mm3] 7.8 ± 8.7 9.9 ± 9.5 0.276
Necrotic core [mm3] 14.2 ± 12.7 22.1 ± 19.9 0.045
Fibrous [%] 61.5 ± 9.8 58.8 ± 10.2 0.194
Fibrofatty [%] 16.6 ± 9.7 12.4 ± 8.4 0.018
Dense calcium [%] 7.8 ± 6.6 9.3 ± 6.5 0.242
Necrotic core [%] 14.3 ± 8.7 19.5 ± 9.1 0.005
Lesion analysis at MLA:
Fibrous [mm2] 4.6 ± 2.6 4.8 ± 2.9 0.675
Fibrofatty [mm2] 1.3 ± 1.1 1.2 ± 1.6 0.919
Dense calcium [mm2] 0.4 ± 0.3 0.6 ± 0.6 0.081
Necrotic core [mm2] 1.1 ± 0.8 1.6 ± 1.3 0.059
Fibrous [%] 61.6 ± 10.5 58.3 ± 14.3 0.244
Fibrofatty [%] 16.7 ± 10.8 12.7 ± 11.2 0.090
Dense calcium [%] 6.1 ± 5.2 8.9 ± 9.9 0.159
Necrotic core [%] 15.8 ± 10.2 20.0 ± 11.1 0.064
Lesion type: 0.015
Pathologic intimal thickening 1 (3.7%) 15 (7.0%)
Fibrocalcific atheroma 10 (37.0%) 34 (15.9%)
Fibrous cap atheroma 8 (30.0%) 51 (23.8%)
Thin cap fibroatheroma 5 (18.5%) 103 (48.1%)
Unclassified 2 (7.4%) 8 (3.7%)
ISR, in-stent restenosis; MLA — minimal luminal area







Age 3.557 1.242–10.192 0.018
hs-CRP 3.334 1.158–9.596 0.026
% NCV 0.430 0.121–1.530 0.193
% FFV 1.175 0.328–4.207 0.804
Beta-blockers 0.364 0.100–1.331 0.127
This multivariate analysis included age, hs-CRP, beta-blockers, % NCV 
and % FFV as variables; hs-CRP — high-sensitivity C-reactive protein; 
NCV — necrotic core volume; FFV — fibrofatty volume
tions, more unstable angina, higher angina class, 
more ostial lesions, multivessel disease, calcified 
lesions and complex lesions observed in older 
patients. This finding is consistent with this study.
The inflammatory marker hs-CRP is known to 
be associated with ISR; this was also shown in our 
study. The increased baseline levels of acute-phase 
proteins are a marker for hyperresponsiveness of 
the inflammatory system to nonspecific stimuli 
[19]. After acute injury, the inflammatory response 
begins with vascular wall penetration of leukocytes 
followed by smooth muscle cell migration and hy-
perplasia. Finally, these processes lead to excessive 
neointimal hyperplasia [20]. Therefore, increased 
hs-CRP reflects an exaggerated response to coro-
nary stenting and is thus is correlated with ISR in 
this study, whereas higher inflammatory coronary 
plaque composition was not.
There were several limitations in this study. 
At first, follow-up CAG was performed usually 
9 months after PCI. This could not evaluate the ISR 
due to neo-atheroslcerosis, which can occur very 
late after stenting. Secondly, we did not evaluate 
post-stent IVUS and follow up IVUS examination. 
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This information would be important to reveal pos-
sible stent underexpansion, which is an important 
factor of ISR. However, we would like to suggest 
the plaque component regarding ISR, not the stent 
underexpansion and/or stent edge problems.
Conclusions
In-stent restenosis was not associated with 
baseline coronary plaque composition but was 
associated with old age and increased expression 
of the inflammatory marker hs-CRP in this study. 
The present results suggest that the older groups 
that have increased hs-CRP expression tend to 
have higher ISR rates; therefore, these groups 
should exhibit better clinical outcomes with proper 
angioplasty and appropriate medication, such as 
anti-inflammatory drugs.
Conflict of interest: None declared
References
1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents 
versus standard stents in patients with stenosis in a native 
coronary artery. N Engl J Med. 2003; 349(14): 1315–1323, 
doi: 10.1056/NEJMoa035071, indexed in Pubmed: 14523139.
2. Stettler C, Wandel S, Allemann S, et al. Outcomes associated 
with drug-eluting and bare-metal stents: a collaborative network 
meta-analysis. Lancet. 2007; 370(9591): 937–948, doi: 10.1016/
S0140-6736(07)61444-5, indexed in Pubmed: 17869634.
3. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, et al. DIABETES 
Investigators. Randomized comparison of sirolimus-eluting stent 
versus standard stent for percutaneous coronary revasculari-
zation in diabetic patients: the diabetes and sirolimus-eluting 
stent (DIABETES) trial. Circulation. 2005; 112(14): 2175–2183, 
doi: 10.1161/CIRCULATIONAHA.105.562421, indexed in Pub-
med: 16203930.
4. Stone GW, Ellis SG, Cannon L, et al. Comparison of a poly-
mer-based paclitaxel-eluting stent with a bare metal stent in 
patients with complex coronary artery disease: a randomized 
controlled trial. JAMA. 2005; 294(10): 1215–1223, doi: 10.1001/
jama.294.10.1215, indexed in Pubmed: 16160130.
5. Cosgrave J, Agostoni P, Ge L, et al. Clinical outcome following 
aleatory implantation of paclitaxel-eluting or sirolimus-eluting 
stents in complex coronary lesions. Am J Cardiol. 2005; 96(12): 
1663–1668, doi: 10.1016/j.amjcard.2005.07.082, indexed in Pub-
med: 16360354.
6. Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the 
drug-eluting stent era. J Am Coll Cardiol. 2010; 56(23): 1897–1907, 
doi: 10.1016/j.jacc.2010.07.028, indexed in Pubmed: 21109112.
7. Costa MA, Simon DI. Molecular basis of restenosis and 
drug-eluting stents. Circulation. 2005; 111(17): 2257–2273, 
doi: 10.1161/01.CIR.0000163587.36485.A7, indexed in Pub-
med: 15867193.
8. Rogers C, Welt FG, Karnovsky MJ, et al. Monocyte recruitment 
and neointimal hyperplasia in rabbits. Coupled inhibitory ef-
fects of heparin. Arterioscler Thromb Vasc Biol. 1996; 16(10): 
1312–1318, indexed in Pubmed: 8857930.
9. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiother-
apy to inhibit restenosis after coronary stenting. N Engl J Med. 
1997; 336(24): 1697–1703, doi: 10.1056/NEJM199706123362402, 
indexed in Pubmed: 9180087.
10. Stone GW, Kandzari DE, Mehran R, et al. Percutaneous reca-
nalization of chronically occluded coronary arteries: a consen-
sus document: part I. Circulation. 2005; 112(15): 2364–2372, 
doi: 10.1161/CIRCULATIONAHA.104.481283, indexed in Pub-
med: 16216980.
11. Mintz GS, Nissen SE, Anderson WD, et al. American College of 
Cardiology Clinical Expert Consensus Document on Standards 
for Acquisition, Measurement and Reporting of Intravascular 
Ultrasound Studies (IVUS). A report of the American College 
of Cardiology Task Force on Clinical Expert Consensus Docu-
ments. J Am Coll Cardiol. 2001; 37(5): 1478–1492, indexed in 
Pubmed: 11300468.
12. Lee CS, Seo YH, Yang DJu, et al. Positive Vascular Remodeling in 
Culprit Coronary Lesion is Associated With Plaque Composition: 
An Intravascular Ultrasound-Virtual Histology Study. Korean 
Circ J. 2012; 42(11): 747–752, doi: 10.4070/kcj.2012.42.11.747, 
indexed in Pubmed: 23236326.
13. Sakakura K, Nakano M, Otsuka F, et al. Comparison of pathol-
ogy of chronic total occlusion with and without coronary artery 
bypass graft. Eur Heart J. 2014; 35(25): 1683–1693, doi: 10.1093/
eurheartj/eht422, indexed in Pubmed: 24126875.
14. Karas SP, Gravanis MB, Santoian EC, et al. Coronary intimal 
proliferation after balloon injury and stenting in swine: an animal 
model of restenosis. J Am Coll Cardiol. 1992; 20(2): 467–474, 
indexed in Pubmed: 1634687.
15. Toutouzas K, Colombo A, Stefanadis C. Inflammation and reste-
nosis after percutaneous coronary interventions. Eur Heart J. 
2004; 25(19): 1679–1687, doi: 10.1016/j.ehj.2004.06.011, indexed 
in Pubmed: 15451145.
16. Meuwissen M, Piek JJ, van der Wal AC, et al. Recurrent unstable 
angina after directional coronary atherectomy is related to the 
extent of initial coronary plaque inflammation. J Am Coll Cardiol. 
2001; 37(5): 1271–1276, indexed in Pubmed: 11300434.
17. Libby P. Inflammation in Atherosclerosis. Arterioscler Thromb 
Vasc Biol. 2012; 32(9): 2045–2051, doi:  10.1161/atvbaha.108. 
179705.
18. De Gregorio J, Kobayashi Y, Albiero R, et al. Coronary artery 
stenting in the elderly: short-term outcome and long-term an-
giographic and clinical follow-up. J Am Coll Cardiol. 1998; 32(3): 
577–583, doi: 10.1016/s0735-1097(98)00287-3.
19. Liuzzo G, Buffon A, Biasucci LM, et al. Enhanced inflamma-
tory response to coronary angioplasty in patients with severe 
unstable angina. Circulation. 1998; 98(22): 2370–2376, indexed 
in Pubmed: 9832480.
20. Lasave LI, Abizaid AAC, Paiva e Maia J, et al. [Relationship 
between plasma C-reactive protein level and neointimal hy-
perplasia volume in patients with zotarolimus-eluting stents. 
Volumetric analysis by three-dimensional intracoronary ultra-
sound]. Rev Esp Cardiol. 2007; 60(9): 923–931, indexed in Pub-
med: 17915148.
